Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

1 Sept 2007

Abstract excerpt

Some somatic mutations, especially those in genes encoding tyrosine kinases, are central to the biology of specific cancers. In such instances, these “driver” mutations lead to the production of mutated enzymes, which then serendipitously serve as excellent substrates for targeted therapies.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17785543
DOI: 10.1158/1078-0432.ccr-07-1387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal MethodPMID 17785543Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.Semantic proximity Read ↗

EGFR testing in lung cancer is ready for prime time.Semantic proximity Read ↗

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.Semantic proximity Read ↗

Germline mutations in lung cancer and personalized medicine.Semantic proximity Read ↗

Emerging gene mutation targets in lung cancer.Semantic proximity Read ↗

Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.Semantic proximity Read ↗

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Semantic proximity Read ↗

How and when to use genetic markers for nonsmall cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.